2026-04-14T07:07:50Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/124132025-02-04T00:37:04Zcom_2072_378070com_2072_378040col_2072_378092

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01 SIENA, SALVATORE Raghav, Kanwal Yamaguchi, Kensei Nishina, Tomohiro Masuishi, Toshiki Elez, Elena Institut Català de la Salut [Siena S] Department of Oncology and Hemato-Oncology, Università degli Studi di Milano and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. [Raghav K] Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. [Masuishi T] Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan. [Yamaguchi K] The Cancer Institute Hospital of JFCR, Tokyo, Japan. [Nishina T] National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan. [Elez E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain Vall d'Hebron Barcelona Hospital Campus Avaluació de resultats (Assistència sanitària) Medicaments antineoplàstics - Ús terapèutic Immunoteràpia Recte - Càncer - Tractament Còlon - Càncer - Tractament Marcadors tumorals Metàstasi CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms Other subheadings::Other subheadings::Other subheadings::/drug therapy DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento Biomarkers; Clinical outcomes; Metastatic colorectal cancer Biomarcadors; Resultats clínics; Càncer colorectal metastàtic Biomarcadores; Resultados clínicos; Cáncer colorrectal metastásico DESTINY-CRC01 (NCT03384940) was a multicentre, open-label, phase 2 study that investigated the safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing metastatic colorectal cancer (CRC). The present exploratory biomarker analysis aims to investigate relationships between biomarkers and clinical outcomes in patients with HER2-positive (immunohistochemistry [IHC] 3+ or IHC 2+ and in situ hybridization [ISH] positive) Cohort A (N = 53) of DESTINY-CRC01. Higher levels of HER2 biomarkers in baseline tissue and liquid biopsies, including HER2 status (IHC/ISH), HER2/CEP17 ratio, HER2 ISH signals, HER2 H-score, plasma HER2 (ERBB2) amplification status, HER2 adjusted plasma copy number, and HER2 extracellular domain correlate with antitumor activity (indicated by objective response rate, progression-free survival, and overall survival) of T-DXd. Baseline circulating tumor DNA (ctDNA) analysis suggests antitumor activity of T-DXd in patients who had baseline activating RAS, PIK3CA, or HER2 mutations detected in ctDNA. 2025-01-15T07:49:58Z 2025-01-15T07:49:58Z 2024-11-25 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, et al. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024 Nov 25;15:10213. 2041-1723 https://hdl.handle.net/11351/12413 10.1038/s41467-024-53223-3 39587050 001364059600021 http://hdl.handle.net/11351/12413 eng Nature Communications;15 https://doi.org/10.1038/s41467-024-53223-3 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf Nature Portfolio Scientia